Cancer Gene Therapy, published by SpringerNature, stands at the forefront of research in the fields of cancer research, molecular biology, and molecular medicine. With a robust impact factor reflecting its significant influence—ranking in the Q2 category for cancer research and Q1 for both molecular biology and molecular medicine—it serves as an essential resource for scholars and practitioners alike. Since its inception in 1994, the journal has dedicated itself to advancing the understanding and therapeutic application of genetic innovations in oncology. Notably, it holds distinguished Scopus ranks, placing it among the top tier journals in its categories, underscoring its importance to the scientific community. While open access options are not available, the compelling research published here offers invaluable insights into the latest advancements and strategies in cancer therapy. Engaging with *Cancer Gene Therapy* not only keeps professionals informed but also inspires future innovations in the quest for effective cancer treatments.

Molecular and Clinical Oncology is a dynamic journal published by SPANDIDOS PUBL LTD, aimed at advancing the understanding of cancer biology and treatment modalities. With an ISSN of 2049-9450 and an E-ISSN of 2049-9469, the journal serves as a critical platform for researchers and clinicians dedicated to uncovering novel insights in molecular oncology and enhancing clinical practices. As a testament to its growing influence, the journal has achieved a Q3 ranking in Oncology and a Q4 ranking in Cancer Research for the year 2023, reflecting its commitment to publishing high-quality research. Although currently not an Open Access publication, the journal offers crucial subscription options, ensuring comprehensive access to groundbreaking studies and innovations in the field. With converged years spanning 2018 to 2024, the journal is set to continue enriching the academic community with its valuable contributions, ultimately empowering researchers, professionals, and students engaged in the fight against cancer.

International Journal of Gastrointestinal Intervention is a distinguished open-access journal published by the SOC GASTROINTESTINAL INTERVENTION that has been committed to disseminating critical research since its inception in 2012. Based in the Netherlands, this journal focuses on the dynamic fields of gastroenterology, hepatology, oncology, and radiology, offering a platform for innovative studies and clinical interventions that can significantly impact patient care and medical practice. With its incorporation into Scopus and ranked within the lower quartiles in various categories as of 2023, the journal acknowledges the evolving landscape of medical research and seeks to continually elevate its contributions to knowledge in these specialized areas. By embracing open access since its founding, the journal ensures that cutting-edge research findings are accessible to a global audience, fostering collaboration and knowledge sharing among researchers, professionals, and students. The journal aims to be a premier source of information and a catalyst for advancements in gastrointestinal interventions, making it an essential resource for those dedicated to improving health outcomes in these critical medical fields.

BMJ Open Gastroenterology is a premier open access journal published by the esteemed BMJ Publishing Group, focusing on the dynamic and evolving field of gastroenterology. Established in 2014, the journal has rapidly ascended in stature, reflected in its impressive 2023 Q1 ranking in gastroenterology and its position within the top 25% of journals in the category according to Scopus. With a mission to disseminate high-quality, peer-reviewed research with global significance, the journal provides a vital platform for researchers, professionals, and students alike to share their findings and advancements in gastrointestinal medicine. Operating from its headquarters in London, England, the journal's open access format ensures wide visibility and accessibility of cutting-edge research, making it an invaluable resource for those dedicated to improving patient care and driving innovation in gastroenterological sciences. By engaging with this journal, contributors and readers can stay at the forefront of critical developments in the field, fostering a collaborative environment for knowledge exchange.

Oncologie is a distinguished academic journal published by WALTER DE GRUYTER GMBH, focusing on the dynamic and vital field of oncology. Established in 1999 and continuously published until 2024, this journal provides a platform for high-quality research and advancements in cancer treatment, prevention, and diagnosis. With an ISSN of 1292-3818 and an E-ISSN of 1765-2839, it is indexed in various databases, contributing to its growing visibility. Although categorized in the Q3 quartile for oncology research as of 2023, Oncologie offers essential insights and fosters scholarly dialogue among researchers, professionals, and students interested in oncology. Its unique contributions aim to bridge the gap between theoretical frameworks and clinical applications, making it a valuable resource for those seeking to advance their knowledge and expertise in cancer research.

Gynecologic Oncology Reports is a pivotal interdisciplinary journal published by Elsevier Science Inc. that has been dedicated to advancing the understanding of women's health since its inception in 2014. This Open Access journal, available to a global audience, facilitates the dissemination of high-quality research in the fields of gynecology and oncology, allowing for the free exchange of knowledge and fostering collaboration among researchers, clinicians, and students. With an impact factor reflective of its commitment to clinical relevance, Gynecologic Oncology Reports holds a Q3 ranking in both obstetrics and gynecology as well as oncology categories, contributing to its visibility and the prestige of published work. Situated in the Netherlands and operating within an open-access framework, it ensures that critical findings and advancements reach a broad readership. The journal serves as a vital resource for those aiming to stay at the forefront of gynecologic oncology, promoting improved patient outcomes through cutting-edge research. As it converges towards its 10th anniversary in 2024, Gynecologic Oncology Reports continues to be an essential platform for scholarly communication in this important field.

INTERNATIONAL JOURNAL OF CANCER, published by Wiley, stands as a premier platform for the dissemination of cutting-edge research in the fields of cancer research and oncology. With an impressive impact factor reflecting its rigorous peer-review process and significant contribution to the scientific community, this journal is categorized in Q1 for both Cancer Research and Oncology as of 2023. It boasts notable rankings, being placed 38th among 404 journals in Medicine - Oncology and 32nd among 230 in Biochemistry, Genetics, and Molecular Biology - Cancer Research, positioning it within the 90th and 86th percentiles, respectively. Since its inception in 1966 and continuing to 2024, the journal has played a pivotal role in advancing our understanding of cancer biology, treatment modalities, and innovative therapeutic approaches. While it operates under a subscription model, the journal is committed to making valuable research accessible to a broader scientific audience. Researchers, professionals, and students alike will find the INTERNATIONAL JOURNAL OF CANCER an essential resource for staying abreast of the latest advancements in cancer science.

JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, published by Springer, is a prestigious peer-reviewed journal dedicated to advancing the fields of cancer research and clinical oncology. With an impact factor reflecting its significance within the academic community, the journal operates under a rigorous quality standard and offers a wealth of knowledge spanning from 1979 and continuing through 2025. With its comprehensive scope, it encompasses a wide array of topics including novel therapeutic strategies, clinical trials, and cutting-edge research methodologies, making it an essential resource for researchers, practitioners, and students alike. The journal’s category quartiles highlight its competitive edge, ranking Q2 in Cancer Research and Q1 in Medicine (miscellaneous) as of 2023. This positioning underscores its role at the forefront of oncology discourse. Through this journal, contributors and readers alike engage with impactful research that informs clinical practices and enhances patient care in oncology. Access to the journal’s content, although not open access, ensures curated and high-quality insights available to the academic and professional community.

ORAL ONCOLOGY is a leading peer-reviewed journal published by Elsevier, dedicated to advancing the field of oncology with a specific focus on oral diseases and cancers. Since its inception in 1996, this esteemed journal has provided a platform for high-quality research that addresses critical issues in oral surgery, cancer research, and related disciplines. With impressive rankings in Q1 in Oncology and Q1 in Oral Surgery, and recognized as Rank #1 in Dentistry and Oral Surgery by Scopus, ORAL ONCOLOGY consistently publishes impactful articles that contribute significantly to our understanding of oral cancers. The journal is committed to sharing pioneering findings that enhance clinical practices and improve patient outcomes. As a non-open access journal, it provides readers with exclusive access to cutting-edge research, ensuring that professionals, researchers, and students are at the forefront of developments in the field. Situated in the United Kingdom, ORAL ONCOLOGY serves as an indispensable resource for those dedicated to advancing oral health and oncology research through rigorous scientific inquiry and collaboration.

PATHOLOGY & ONCOLOGY RESEARCH is a prominent international journal published by FRONTIERS MEDIA SA, dedicated to advancing the fields of pathology and oncology. Operating from the Netherlands, with a distinguished address in Switzerland, this journal plays a crucial role in disseminating significant research findings and insights from 1995 to 2024. With an ISSN of 1219-4956 and E-ISSN of 1532-2807, it is indexed in well-respected databases, facilitating access to a global audience of researchers and practitioners. Notably, the journal ranks in the Q3 category for Cancer Research (2023), while being recognized in the Q2 categories for both Medicine (Miscellaneous), Oncology, and Pathology and Forensic Medicine, reflecting its authoritative status in these vital disciplines. Scopus rankings further highlight its influence, with notable percentiles across various fields. Although it follows a subscription model, the journal remains committed to publishing high-quality, peer-reviewed research that bridges conceptual gaps and encourages further exploration in oncology and diagnostic pathology, making it an indispensable resource for academics and professionals engaged in these critical areas of medicine.